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Abstract 
Quantum dots (QDs) are semiconductor nanoparticles with very interesting optical 
properties, like high quantum yield or narrow and size−tuneable fluorescence spectra. Current 
applications of QDs are widespread, being their use as fluorescence labels in bioassays one of the 
most promising. These nanoparticles are usually conjugated to highly specific biomolecules like 10 
antibodies, oligonucleotides, enzymes or aptamers to improve assay selectivity. In this review, QD 
surface passivation, conjugation to biomolecules, and purification strategies are discussed with 
special emphasis to the development of QD−based immunoassays for the detection of low 
molecular weight compounds given the relevance of this sort of analytes in health, food safety, 
pharmaceutical, or environmental monitoring areas. The aim of this review is to summarize the 15 
main achievements attained so far and to initialize researchers in the field of antibody−based 
assays employing QDs as labels, such as fluorescence−linked immunosorbent assay (FLISA), 
fluorescence (or Förster) resonance energy transfer (FRET), immunochromatographic methods, 
and immunosensors. 
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1. Introduction 
Quantum dots (QDs) are semiconductor nanoparticles with particular electronic and optical 
properties that have been widely studied and applied in the last decade. The typical diameter of 30 
QDs is in the 1−20 nm range and they can contain from 100 to 100.000 atoms per nanoparticle. 
Some of the most attractive properties of QDs are high quantum yield, high molar extinction 
coefficients, broad absorption spectra, narrow and symmetric emission bands (30−50 nm), large 
effective Stokes shifts and high resistance to photobleaching and chemical degradation (Algar et 
al., 2010; Rosenthal et al., 2011). The special characteristics of these nanomaterials are explained 35 
by the strong confinement of electrons when the radius of the particle is smaller than the exciton 
Bohr radii. Different applications can be found for QDs, such as in the photovoltaic, thermoelectric 
or light−emitting diode industries, but their applications in life sciences have revolutionized the 
state of the art of many biological assays, including fluorescence−linked immunosorbent assays 
(FLISA), fluorescence resonance energy transfer (FRET) assays, immunosensors, DNA probes, or 40 
imaging, currently being a real alternative to the use of traditional organic dyes, enzymatic labels, 
or isotopic markers.  
QDs are very versatile labels because their photoluminescence emission band can be 
easily tuneable, from the UV to the IR regions, by the selection of the particle size (1−12 nm) and 
the nature and composition of the nanoparticle, which can be synthesized with binary alloys of 45 
atoms from 12−16 (ZnS, CdS, CdSe, HgS), 13−15 (GaAs, InP, InAs, GaN) or 14−16 (PbTe, PbSe) 
groups (see Figure 1). Ternary alloys of CdZnS, CdSSe, InNP or InGaAs have been also 
synthesized with analogous properties (Medintz et al., 2005). The aforementioned versatility in the 
QD emission wavelength and the fact that they can be excited by a single wavelength makes 
possible their simultaneous use as fluorescent labels of different processes running at the same 50 
time. Moreover, the fluorescence of QDs shows a very narrow emission band, so different markers 
can be potentially employed in different bioassays for the detection of several compounds in 
multiplexing studies without spectral interferences. Most of these bioassays involve the conjugation 
of QDs to a selective biomolecule, like an antibody. In this sense, several QD−based 
immunoassays have been developed for the detection and quantification of a wide range of 55 
pathogens, proteins and toxins, but only few of them have been proposed for the analysis of 
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small−sized analytes (Algar et al., 2010; Biju et al., 2008; Gill et al., 2008). These challenging 
analytical targets, immunochemically named haptens, encompass a wide range of 
physicochemically different compounds like veterinary drugs, pesticide and food additive residues, 
persistent organic pollutants, explosives and war agents, mycotoxins, environmental and industrial 60 
contaminants, numerous metabolites in biological fluids, hormones, packaging components, drugs 
of abuse, etc. The analytical determination of these chemicals is largely performed by accredited 
laboratories that use instrumental procedures, most of them based on chromatographic 
separations. Considering the high number of samples that are required to be analysed and the low 
to moderate sample throughput and high solvent and reagent consumption of those analytical 65 
methodologies, unaffordable economical and human resources are often required. The use of 
immunoanalytical approaches in monitoring programmes are currently deemed feasible and useful 
alternatives to chromatographic instrumental procedures, based on the high sample throughput, 
reduced sample treatment, portability, on−site analytical capability, and the high sensitivity and 
selectivity generally ascribed to these rapid methods (Lee and Kennedy, 2001). Moreover, the use 70 
of immunoassays agrees with the basic principles of the Green Chemistry by minimizing residues 
and waste generation (Armenta et al., 2008). Accordingly, this review will pay special attention to 
the different procedures and methods employed for QD conjugation to antibodies and their 
application to the analysis of small−sized analytes. 
 75 
1.1. Evolution of quantum dot research 
Despite the first published papers concerning the properties of QDs date back to the 
mid−eighties, we can consider the synthesis studies by Bawendi’s group as the starting point of the 
revolutionary use of QDs, because they first proposed a new and simple synthetic route for the 
preparation of semiconductor nanocrystals of uniform size and shape in macroscopic amounts 80 
(Murray et al., 1993). From that time onwards, the scientific references found in the literature 
concerning QDs increase almost exponentially (Figure 2), with more than 4000 papers published 
each year over the last decade, and more than 6000 annually in the last five−year period (ISI Web 
of Knowledge database, Thomson Reuters). This huge productivity on the development and 
improvement of new applications involving QDs points out the wide acceptance by the scientific 85 
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community of these innovative fluorescent nanoparticles due to the sound expectations of getting 
more sensitive, simple and robust immunosensing systems.  
Later on, Alivisatos’ and Nie’s groups simultaneously published the coupling of QDs to 
different biomolecules (Bruchez et al., 1998; Chan and Nie, 1998), thus opening the door to 
different pioneer biosensing schemes using QDs as tracers, such as i) the development of a FLISA 90 
for the determination of 2,4,6−trinitrotoluene (TNT) (Goldman et al., 2002a); ii) the design of a 
FRET maltose sensor (Medintz et al., 2003); iii) the use of CdSe/ZnS QDs for in vivo imaging 
studies (Larson et al., 2003); iv) the development of bioluminescence resonance energy transfer 
(BRET) applications (So et al., 2006); v) the use of semiconductor nanocrystals for the 
development of electrochemical (Liu et al., 2004) and electrochemiluminescent (Jie et al., 2008a) 95 
immunosensors; or vi) the recent implementation of QDs as labels in fibre−optic evanescent wave 
biosensors (Zhang et al., 2010a). 
The classification of published scientific papers by thematic areas is shown in Figure 2. 
About 30% of articles dealing with QDs have been published in Physics, 16% in Material Sciences, 
13% in Chemistry and 10% in Engineering journals, while the rest were published in areas such as 100 
Science & Technology, Optics, Spectroscopy or Biochemistry. Considering the country of origin of 
these studies, most of them were carried out in the United States (26%), People’s Republic of 
China (13%), Germany (13%), Japan (11%), and France (6%) (ISI Web of Knowledge database, 
Thomson Reuters). 
Finally, the article/review ratio of published papers in scientific journals is as high as 19.3, a 105 
clear indicator of the huge interest of the scientific community to spread the knowledge and 
advances attained with this kind of nanoparticles. 
 
2. Synthesis of quantum dots 
As it was previously mentioned, the synthesis of QDs dates back to the eighties, when they 110 
were first prepared by the Stranski−Krastanov or lithographic top−down techniques. However, 
those methods showed a lack of reproducibility, with nanoparticles heterogeneous in size and with 
elevated surface defects (Li, 2008). In 1993, Bawendi and co−workers introduced the currently 
well−common synthesis of QDs based on the injection of organometallic precursor molecules into 
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trioctylphosphine oxide (TOPO) and trioctylphosphine (TOP) surfactants at high temperature 115 
(190−320 ºC) (Murray et al., 1993). Under these conditions, nucleation occurs rapidly and the 
nanoparticle size can be easily tuned by a simple kinetic control (see Figure 3). The resulting QDs 
are very hydrophobic because the nanoparticles are coated with nonpolar surfactant molecules, 
where the phosphine groups interact with the core of the particle and the aliphatic chains are 
positioned to the external surface.  120 
In 2000, Peng’s group demonstrated that the presence of small amounts of impurities in the 
technical grade TOPO (essentially alkyl phosphonic and phosphinic acids) coordinated to cadmium 
and decreased the growth of particles. Accordingly, the addition of a certain amount of compounds 
like hexylphosphonic acid (HPA) in the reaction allowed decreasing the growth of QDs, so a very 
homogenous particle size distribution could be obtained. Nevertheless, the use of HPA at a 125 
concentration higher than 5% may produce rod−like nanoparticles, which does not maintain the 
electron confinement properties (Peng et al., 2000). Afterwards, dimethyl cadmium was replaced 
by other not pyrophobic, less toxic, and more stable cadmium precursors, such as oxide (Peng and 
Peng, 2001), acetylacetonate (Clapp et al., 2006a) or myristate (Carion et al. 2007), with no 
alterations in the final QD properties. Table 1 shows some of the most employed colloidal synthetic 130 
procedures with the required reagents and the main experimental conditions. 
The colloidal synthesis of CdSe crystals using high temperatures and the TOP/TOPO 
system is one of the most refined and extended, and the so–produced QDs have been widely 
characterized. Nonetheless, additional synthetic procedures have been proposed using aqueous 
systems and lower temperatures. These methods are essentially based on the use of different 135 
cadmium or zinc inorganic salts and sodium sulphide or sodium hydrogen selenide precursors 
dissolved in water with different capping agents. The thiol−containing amino acid cysteine is 
usually employed as capping in this kind of methodology because it has a high solvation effect, 
where the thiol group stabilizes the QD surface and the amino acid group is oriented to the 
exterior, providing a net charge that allows the dissolution of QDs in water. Many other capping 140 
compounds can also be employed, such as polyphosphates (Chen and Rosenzweig, 2002), 
1−thioglycerol (Chen and Rosenzweig, 2002; Vossmeyer et al., 1994), poly(N−vinyl−2−pyrrolidone) 
(Li et al., 2006), 3−mercaptopropionic acid (Chen et al., 2010; Wang et al. 2009b), or thyoglycolic 
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acid (TGA) (Bao et al., 2004). Table 1 also shows a brief summary of the precursors and the 
employed conditions for most−common aqueous synthesis of QDs. 145 
Transition-metal ion doped QDs have been widely studied and reported showing many 
advantages when compared to traditional QDs, such as i) high thermal and environmental stability, 
ii) large Stoke shifts between excitation and emission wavelengths, and iii) high excited state 
lifetime which allows phosphorescent measurements (Norris et al., 2001; Yang et al., 2005; Sotelo-
González et al., 2012). Doping of Mn and Cu ions in different QDs like Mn:ZnS, Mn:ZnSe, 150 
Mn:CdSe, Cu:ZnSe, Cu:InP/ZnSe or CdS/Mn:ZnS have been widely studied and reported (Karan 
et al., 2010), where Mn−doped QDs result in orange−yellow emission particles, and Cu−doped 
QDs give a size-tunable emission spectra depending on the size and nature of the host 
nanocrystals. 
 Purification of QDs is usually made by precipitation with methanol or ethanol, centrifugation, 155 
and removal of the supernatant, which mainly contains unreacted precursors and other impurities. 
Some authors use the size−selective precipitation method, where small amounts of different polar 
solvents (ethanol, 2−propanol, or acetone) are employed to precipitate polydisperse mixtures of 
CdS QDs. This procedure is repeated until monodisperse fractions are obtained (Vossmeyer et al., 
1994). Dialysis is preferred in some cases to avoid difficulties in redispersing the precipitated QDs, 160 
like in the aqueous synthesis of polyphosphate−capped CdS QDs (Chen and Rosenzweig, 2002).  
 
2.1. Core/shell quantum dots 
Many studies have demonstrated that the passivation of CdSe nanoparticles with a ZnS, 
CdS or ZnSe inorganic shell strongly increases the luminescence of the QDs to a 35−50% 165 
quantum yield (Danek et al., 1996; Hines and Guyot−Sionnest, 1996). Accordingly, the use of 
protecting shells on core QDs has been widely employed in the synthesis of these nanoparticles. 
The ZnS shell layer has additional positive effects, such as: i) protection of the CdSe core surface 
against oxidation; ii) reduction of Cd toxicity by suppressing the dissolution of free ions; iii) increase 
in photostability; and iv) recombination of surface core defects. The ZnS shell layer directly grows 170 
onto the QD surface, but the size of the core particle is not modified, so the luminescence 
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properties of the QDs are preserved and only a small shift (< 5 nm) in the fluorescence maximum 
wavelength is observed.  
The standard procedure to synthetize CdSe/ZnS (core/shell) QDs uses diethyl zinc (or 
dimethyl) and hexamethyldisilathiane in TOP/TOPO (see Table 1), so special attention must be 175 
paid to the use of organometallic compounds owing to their pyrophobic character. Nevertheless, 
other coating procedures have been developed by using less hazardous oleate precursors (Carion 
et al., 2007). The coating procedure is entirely compatible with the previous core synthesis and it 
can be performed with (Danek et al., 1996; Dabboussi et al., 1997) or without (Hasani et al., 2010; 
Hines and Guyot−Sionnest, 1996) a previous purification step with similar results, so both methods 180 
are widely accepted. The highest photoluminescence increase is obtained with a thin ZnS shell 
based on only 1−2 monolayers, whereas in the case of thicker shells the QD core is more stable 
against oxidation or extreme buffer conditions, so a compromise must be adopted between the 
shell thickness and the nanoparticle required properties (Medintz  et al., 2005). 
 185 
2.2 Quantification of quantum dots 
The concentration of the QDs after a colloidal synthesis procedure is difficult to determine 
by gravimetric or elemental composition methods, considering the unknown number of ligand 
molecules that are conjugated to every nanoparticle. For this purpose, Peng’s group provided 
empiric equations to estimate the extinction coefficients for CdTe, CdSe, and CdS QDs, so their 190 
concentration can be easily calculated by the Lambert−Beer’s law (Yu et al., 2003). In the case of 
water soluble QDs, Peng’s group equations have no validity, because the spectrum is affected by 
the employed capping compound, but also by pH or ionic strength of the working buffer. Alternative 
strategies have been recently proposed for the quantification of QDs in solution, like the 
single−particle counting of streptavidin−coated CdSe/ZnS QDs (Zhang and Johnson 2008a) or 195 
phage−based assays to detect mercaptoacetic acid−coated CdSe/ZnS QDs (Mardyani and Chan, 
2009). 
 
 
 200 
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3. Surface functionalization 
The most extended synthesis of QDs results in very hydrophobic nanoparticles that are only 
soluble in non−polar solvents such as chloroform or toluene. However, almost all biological 
applications require the use of aqueous buffered solutions, so QDs must be modified in order to 
increase their water solubility while keeping their optical properties. This double purpose can be 205 
achieved by changing the surface nature of the nanoparticles, avoiding a direct modification of the 
particle core. Usually, water solubilisation of QDs is attained by the introduction of functional 
groups (carboxylate, amino, or hydroxyl) over its surface in order to have a total net charge. 
Additionally, this modification of the QD surface makes easy a future conjugation to biomolecules. 
Table 2 shows the most extended strategies for the functionalization of the QD surface. They are 210 
based on two main approaches, hydrophilic ligand exchange or encapsulation using hydrophobic 
interactions. 
First approach consists in the substitution of TOP/TOPO molecules by hydrophilic ligands 
that contain a thiol group and a polar substituent, so the thiol group interacts with the QD surface 
and replaces the TOP/TOPO ligands, while the charged groups are oriented outside, increasing 215 
the water solubility. Originally, monodentate thiols were employed as ligands, but the use of 
bidentate thiol groups are currently preferred because of their stronger and more robust interaction 
with the QD surface, being the dihydrolipoic acid (DHLA) one of the most employed ligands (Clapp 
et al., 2006b; Mattoussi et al., 2000). 
Second approach is based on the encapsulation of the original QD, solvated by TOP/TOPO 220 
ligands, with amphiphilic polymers or phospholipids that combines both hydrophobic alkyl chains 
and hydrophilic groups. In this case, non−specific hydrophobic interactions are responsible for 
linking the alkyl chains of both, the polymer/phospholipid and the phosphine ligands, while the 
polar groups are place outside the nanoparticle conferring water solubility. The employed 
amphiphilic polymers are mostly based on a poly(maleic anhydride) backbone with a hydrophobic 225 
side chain, such as tetradecene (Pellegrino et al., 2004), octadecane (Yan et al., 2010) or dodecyl 
(Fernandez−Argüelles et al., 2007). These polymers coat the QD surface using an amine−type 
cross−linker, such as bis(hexamethylene)triamine. Recently, other polymer coatings have been 
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evaluated, like alginate, chitosan, carrageenan or polyvinyl pyrrolidone, in order to obtain water 
soluble QDs with reduced toxicity (Peretz et al., 2011).  230 
The two aforementioned functionalization strategies are adequate for the solubilisation of 
QDs in water, so the most appropriate procedure must be selected depending on the intended 
future application. The main difference between the two procedures is the final size of the coated 
QD; whereas the use of the ligand exchange strategy does not modify the particle size, 
encapsulation methods notably increase the particle diameter due to the size of the TOP/TOPO 235 
layer plus the polymer or phospholipid coating (see Figure 4). Additional differences between those 
methods are: i) monodentate thiols are very easy to synthesize, but the obtained coated−QDs 
aggregate in few days and have short shelf lives, while the use of bidentate thiols improves the 
long−term stability from weeks to years; ii) amino derivatives are adequate for working at acid pH, 
while carboxylate derivatives are more tolerant to basic pH; iii) silica and polymer/phospholipid 240 
coatings are more stable against photobleaching and they have a higher pH stability, even though 
large nanoparticles are obtained (20−30 nm diameter) and FRET application is disabled; and iv) 
large size QDs with polymer coating shows a lower toxicity for in vivo applications than 
small−ligand coatings (Medintz et al., 2005). 
 245 
4. Commercial quantum dots 
Several companies offer semiconductor nanocrystals of different composition, size and 
surface functionalization. A summary of the most relevant information about the commercially 
available QDs is shown in Table 3. Most commercialized QDs are composed by CdSe or CdS 
alloys, and they cover a wide range of fluorescence wavelengths. However, there are some 250 
exceptions, such as the availability of same−sized QDs with different emission wavelengths based 
on CdSexS(1−x) alloys, or the commercialization of InGaP, PbS and other cadmium−free QDs. 
These nanoparticles are hydrophobic, usually dissolving in toluene, but they can be also 
purchased as water−soluble QDs functionalized with carboxyl, amino or hydroxyl groups. In some 
cases, QDs can be acquired biotinilated or bioconjugated to streptavidin and to a variety of 255 
secondary antibodies, which allow a rapid and easy development of fluorescent immunoassays. 
However, in the case of multiplexed studies or when the use of a QD−labelled specific protein (or 
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antibody) is mandatory, bioconjugation of the QD with the required biomolecule must be carried 
out. 
 260 
5. Bioconjugation of quantum dots  
QDs can be conjugated with different biomolecules, such as proteins, antibodies, aptamers, 
oligonucleotides, etc., and as a result a unique nanoparticle is obtained bringing together the 
properties of both materials, i.e., the optical/electrochemical properties of QDs and the biological 
function of the biomolecule. Antibodies are probably the preferred biomolecules to be bonded to 265 
QDs, considering their huge specificity, affinity, and versatility in the development of different 
immunoassays. Moreover, the possibility to use QDs with different emission wavelength coupled to 
antibodies against diverse antigens makes possible the development of simultaneous multianalyte 
assays. 
An antibody is an immunoglobulin of 150 kDa comprising two of each type of light (~25 270 
kDa) and heavy (~50 kDa) chains covalently linked by disulphide bonds between cysteine 
residues. Two disulphide bonds links the heavy chains, while another one links every light chain to 
its respective heavy chain (see Figure 5). Conjugation of QDs to antibodies is preferentially carried 
out directly taking advantage of the different amino acids in the protein. However, other procedures 
have been developed for indirect conjugations by using a bridge−type molecule, like avidin or 275 
protein G. Whether covalent or not, conjugation should obviously preserve the specific properties 
of both QDs and antibodies. 
The main procedures for the conjugation of QDs with antibodies are described in Figure 6 
and they can be classified into four groups: i) direct conjugation of amino/carboxyl groups using 
active esters; ii) direct conjugation to the QD surface through the antibody thiol groups; iii) indirect 280 
conjugation using avidin as bridge protein and biotinilated antibodies; and iv) indirect conjugation 
using modified protein G as bridge protein. Obviously, the employed QDs should have been 
previously modified in order to gain water solubility and the required functional groups, preferably 
carboxylate or amino groups. 
 285 
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5.1. Conjugation by active esters 
One of the first employed conjugation procedures reported in the scientific literature was 
based on the classical use of active esters, where a free carboxylic group in the functionalized QDs 
is activated with 1−ethyl−3−(3−dimethylaminopropyl)carbodiimide (EDC) and 290 
N−hydroxysuccinimide (NHS) and the non−purified nanoparticle is later made react with the basic 
amino acids of the antibody (Hua et al., 2006). This procedure is very simple, cheap, requires 
common reagents, and is frequently performed in an one−pot reaction; however, the reactivity of 
EDC is optimal in acid buffers, while carboxyl–coated QDs require a basic pH to be water soluble 
(Algar et al., 2010). Another negative aspect is that the antibody orientation is not controlled, so 295 
undesired products can be also obtained, like reaction of the QD with the paratope (or antigen 
binding site) of the antibody leading to poor antigen binding. Stoichiometry of the reaction 
(QD/antibody ratio) must be accurately controlled in order to avoid cross−linking between 
antibodies, and it is usually challenging to control the number of antibodies attached to a single 
nanoparticle, mainly when large−sized polymer−coated QDs are involved. Finally, some 300 
crosslinking and aggregation problems have been observed by some authors using this procedure 
(Medintz et al., 2003; Peng et al., 2009), but nonetheless the method has been widely employed by 
many researchers to bioconjugate, for example, QDs to specific antibodies against estradiol 
(Harma et al., 2007), aflatoxin (Fernandez−Argüelles et al., 2008), deoxynivalenol (Shuping et al., 
2011), microcystin−LR (Zhou et al., 2011) or fluoranthene (Ye et al., 2010). EDC/NHS chemistry 305 
has been also employed in the coating of QDs to electrodes in the development of immunosensors 
(Jie et al., 2008b; Wang et al., 2009a), or in the coupling to the antigen 3,5,6−trichloropyridinol in 
an immunochromatographic assay (Zou et al., 2010). 
 
5.2. Conjugation by activated maleimides and fragmented antibodies 310 
In this procedure, a previous reduction of the antibody is required to increase reactivity. 
Dithiothreitol (DTT) is commonly employed for the reduction of disulphide bonds of antibodies, but 
the reagent concentration must be accurately adjusted in order to break only the disulphide bonds 
between the heavy chains without affecting those keeping together heavy and light chains, thus 
maintaining the antigen recognition area (see Figure 5). The so−obtained one−half antibody (75 315 
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KDa) has two thiol groups available for conjugation. QDs must be previously coated with 
amino−type substituents and 4−(N−maleimidomethyl)cyclohexanecarboxylic acid 
N−hydrosuccinimide ester (SMCC) is commonly employed as crosslinker (0.83 nm length). The 
amino−coated QDs react with the succinimidyl ester group of the crosslinker, whereas the free 
thiols of the antibody fragment attach through the maleimide group. Both reactions require neutral 320 
pH, so special attention must be given to the solubility of amino−coated QDs. By−products and 
unreacted reagents can be removed using desalting columns (Xing et al., 2007). Detailed 
procedures can be easily obtained from the literature and the internet, and a conjugation kit based 
on the aforementioned methodology is currently available from Life Technologies (see Table 3). 
The great advantage of this method is the optimal spatial orientation of the antibody fragment, 325 
because the recognition area is always oriented outside the QD and therefore to reaction medium, 
so the activity of the conjugated antibodies is usually higher than those obtained by the active ester 
method. Nevertheless, some studies have manifested a poor functionality of QD−antibody 
conjugates synthetized using DTT and SMCC chemistry, probably due to the complete reduction of 
the antibodies (Pathak et al., 2007). Recently, a study has shown that the reduction degree of 330 
antibodies only depends on the DTT concentration and not on the time and temperature of the 
reaction (Mahmoud et al., 2011). These authors propose a reduction of DTT concentration in order 
to generate a higher yield of 75 kDa fragments. Additionally, 2−mercaptoethanolamine was 
suggested for a highest efficiency in 75 kDa antibody fragment generation based on a more 
specific reduction of the heavy chain’s disulfide bonds  335 
 
5.3. Indirect conjugation with avidin bridge 
This procedure takes advantage of the strong affinity binding between biotin and avidin. In 
this case, carboxyl−coated QDs (usually capped with DHLA) are employed due to the negative 
global charge exhibited at neutral/basic pHs. Thus, avidin (a highly positively charged protein) can 340 
be easily anchored to negatively charged QDs through electrostatic interactions. Then, 
avidin−coated QDs are stoichiometrically bond to biotinylated antibodies. Other biotin binding 
proteins have been also evaluated, such as neutravidin or streptavidin, but less satisfactory results 
were obtained because of the lower global positive charge of these proteins as compared with 
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avidin (Goldman et al., 2002b). Nevertheless, streptavidin−coated QDs are commercially available 345 
from suitable companies (see Table 3). 
Although the high stability of the involved electrostatic interactions make avidin–coated QDs 
conjugates very suitable for FLISA development, the so–obtained particles have considerable size 
as a consequence of the dimensions of QD, avidin, and the antibody, so this conjugation approach 
may not be adequate for FRET applications. An additional negative aspect of this strategy is that 350 
protein orientation is not strictly controlled because biotin molecules may exist close to the 
antibody recognition area, and also a lack of homogeneity due to the existence of hybrid 
conjugates with very different protein/QD ratios has sometimes been described (Medintz et al., 
2003). 
On−column conjugation has been proposed in order to improve homogeneity in protein/QD 355 
ratios and to avoid cross−linking of conjugates (Clapp et al., 2006b). For this purpose, avidin and 
maltose binding protein (MBP) appended with a positively charged leucine zipper attachment 
domain are simultaneously conjugated to negatively charged QDs by electrostatic assembly, and 
the resulting complex is immobilized on an amylose resin (Mattoussi et al., 2000). Then, 
biotinylated antibodies are added to the column and after a washing step the bioconjugate is eluted 360 
by maltose addition (Clapp et al., 2006b). A novel protocol intended to improve control in the 
conjugation stoichiometry has been recently proposed based on a previous biotinylation of QD and 
antibody in separate reactions, and their later conjugation via an avidin bridge (Peng et al., 2009).  
 
5.4. Indirect conjugation with protein G bridge 365 
 In this case an immunoglobulin−binding biomolecule, protein G, is employed as bridge 
protein between QD and antibody. In order to improve coupling efficiency, some authors have 
engineered protein G to attach a domain with a positively charged leucine zipper, thus allowing for 
electrostatic assembly with negatively charged QDs. The main advantages of this method are: i) 
high stability of the bioconjugate; ii) antibody biotinylation is not required; and iii) protein G interacts 370 
with the constant region of the antibody and leaves the recognition area unaltered and oriented 
outside the QD. As in the case of avidin bridge conjugation, the number of proteins coupled to 
every QD is variable and different population conjugates may be synthetized (Medintz et al., 2003). 
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The use of protein G as bridge biomolecule has been employed in the development of 
FLISAs for 2,4,6−trinitrobenzene and hexahydro−1,3,5−trinitro−1,3,5−triazine explosives (Goldman 375 
et al., 2002c), and also for the simultaneous determination of four toxins: Shiga−like toxin 1, 
staphylococcal enterotoxin B, cholera toxin, and ricin (Goldman et al., 2004).  
 
5.5. Conjugation using polyhistidine peptides 
 This conjugation strategy is based on the direct metal−affinity coordination of polyhistidine 380 
residues with QD zinc atoms, so a direct interaction takes places between the QD surface and the 
biomolecule with an appended polyhistidine tag. The great advantage of this conjugation approach 
is the short distance between QD and the attached protein, thus improving the FRET efficiency, 
while the main drawback is that engineered bioreceptors are required. The direct conjugation of 
CdSe/ZnS QDs with recombinant antibodies bearing polyhistidine tags have been employed for the 385 
development of fluorescent bioassays for the determination of the explosive 2,4,6−trinitrotoluene 
by FLISA (Goldman et al.,  2005a) and FRET (Goldman et al., 2005b). 
 
5.6. Other considerations 
Bioconjugated QDs must be purified after the conjugation procedure in order to remove 390 
unreacted antibodies and undesired compounds.. The most general purification technique is based 
on liquid chromatography using size−exclusion columns and aqueous buffers, but aggregation 
problems and lack of resolution has been often reported (Hua et al., 2006; Trapiella−Alfonso et al., 
2011b).  
As mentioned above, the final antibody/QD ratio is a critical parameter in the bioassay 395 
performance. Although difficult to determine experimentally, this ratio strongly depends on the 
employed conjugation strategy and it can be estimated by UV/vis spectrophotometry (Kattke et al., 
2011) or SDS-PAGE (Pathak et al., 2007; Shen et al. 2007). However, no information about the 
antibody activity is provided, and spectral interferences and synergic effects may induce wrong 
ratios. In fact, there is a controversy upon the effect of the conjugation over the QD optical 400 
properties. While some authors manifest that the fluorescence intensity of QD−antibody conjugates 
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is lower than that of the free QD (Shen et al., 2007), in other cases a higher intensity has been 
reported (Clapp et al., 2006; Ye et al., 2010). 
To conclude, the most adequate conjugation strategy must be selected depending on the 
potential application we are interested in (FLISA, FRET assay, or immunosensor), even though 405 
additional aspects should also be considered, such as simplicity, long–term stability, antibody 
orientation, reagent availability, etc. Table 4 shows a summary of the main advantages and 
drawbacks of the aforementioned evaluated strategies. 
 
6. Quantum dot−based fluorescent immunoassays 410 
The luminescence properties of QDs can be used to detect analytes by using different sort 
of assays. First analytical applications of QDs were based on their use as probes and sensors by 
measuring the enhancement or quenching of the QD luminescence. These changes in 
luminescence are a consequence of a direct interaction of the analyte with the QD surface, so it is 
widely influenced by the nanoparticle coating and the pH and composition of the employed buffer. 415 
This surface interaction is not specific and only small and simple molecules are able to interact with 
the QD surface. Trial and error strategies with extensive batches of different possible analytical 
targets are usually employed. Thus, numerous luminescence procedures (enhancement or 
quenching) have been developed for the determination of inorganic cations or anions,(Lin et al., 
2007), and also for some organic molecules such as spirolactone, tiopronin, dopamine, glucose, 420 
TNT, anthracene, p−nitrophenol, 1−naphtol, methionine or enoxacin (Galian and de la Guardia, 
2009). 
Conjugation of QDs with antibodies was more recently proposed in order to improve the 
selectivity of the developed assays. Many different bioassay formats have been developed using 
QDs as fluorescent tracers, being FLISA and FRET the most employed techniques.  425 
 
6.1. Fluorescence−linked immunosorbent assays 
Enzyme−linked immunosorbent assay (ELISA) is the most extended type of immunoassay 
for low molecular weight chemicals because of its simplicity, reliability, low cost and high sample 
throughput (Bonwick and Smith, 2004). Usually, an enzyme is conjugated to an antibody or to a 430 
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hapten and, after a competitive immunological reaction, the signal generated by the retained 
enzyme is measured and correlated with the analyte concentration. Antibodies and haptens can be 
likewise conjugated to organic fluorescent tracers, like fluorescein or rhodamine, in order to obtain 
FLISAs. However, the use of fluorescent dyes in immunosorbent assays has some limitations, 
such as low photoluminescence quantum yield and poor stability. QDs offers substantial 435 
advantages as labels over organic dyes, such as: i) broad absorption spectra; ii) very narrow 
emission spectra; iii) long fluorescence lifetime; and iv) improved photostability (Algar et al., 2010; 
Galian and de la Guardia, 2009). In fact, QD labels usually provide a 3−fold thinner spectral band, 
a 20−fold brightness, and a 100−fold photostability when compared to rhodamine dyes (Chan and 
Nie, 2008). Other studies have compared the fluorescence intensity and photostability of QDs 440 
against fluorescein, concluding that the QD−based method had similar (Ruan et al., 2011) or even 
better (Zhao et al., 2011) sensitivity than using organic dyes, but the most important improvement 
was the photostability: few minutes for organic dyes versus days for QD fluorescent markers. 
 In the analysis of small organic molecules, the most relevant ELISA formats are: i) the 
antibody−coated competitive ELISA, wherein a competition between the analyte and an 445 
hapten−enzyme conjugate drives the immunoreaction; and ii) the conjugate−coated competitive 
ELISA, which is usually carried out in two separate immunochemical reactions; first a competition 
between the analyte and an immobilized hapten−protein conjugate, and second a detection step 
with labelled−secondary antibody (Esteve−Turrillas et al., 2011; Parra et al., 2011). Consequently, 
these two formats have been widely employed in the development of FLISAs for the analysis of 450 
haptens, replacing the enzyme by a fluorescent QD tag. 
Table 5 shows the QD−based FLISA studies found in the literature for the analysis of small 
analytes. Most of them are based on the use of the conjugate−coated competitive format, 
employing  commercially available QD−labelled secondary antibody conjugates (Chen et al.,  
2009a; Ding et al., 2006; Zhu et al., 2011) or home−made conjugates with ZnS/CdSe (Yuan et al., 455 
2008) and CdTe (Chen et al., 2010b). A slight variation of the indirect competitive format was 
proposed that uses biotin−labelled secondary antibody in combination with QD−streptavidin 
conjugates in two independent steps (Sun et al., 2010). All the aforementioned procedures 
requires the use of secondary antibodies, so more than one step is needed in order to run the 
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analysis; but if the QD is directly conjugated to the specific antibody, the analysis can be run in a 460 
single step (Figure 7). Thus, different studies have been developed using anti−hapten antibodies 
conjugated to QDs. First examples were reported by Goldman and co−workers (2002a, 2002c, 
2005) using TNT as model analyte, where indirect conjugation strategies based on electrostatic 
interactions between negatively charged CdSe–ZnS QDs and positively charged avidin or 
recombinant protein G were employed. Following modification of the nanoparticles, monoclonal 465 
antibodies were bound directly to Protein G−coated QDs, or biotinylated antibodies were captured 
by avidin−coated QDs. Anti−TNT recombinant antibodies with a polyhistidine tag have been also 
directly conjugated to CdSe–ZnS QDs by histidine–zinc coordination and a sensitivity improvement 
was obtained when compared with previous studies (Goldman et al., 2005). 
Anti−sulfamethazine antibodies were conjugated by the activated maleimide method and a 470 
FLISA was developed (Shen et al., 2007). In this case, a generic antibody was employed and other 
related compounds like N4−acetyl sulfamethazine, sulfadimethoxine and sulfamerazine were 
additionally detected. Active ester method was employed for the conjugation of anti−aflatoxin 
(Fernandez−Argüelles et al., 2008) and anti−fluoranthene (Ye et al., 2010) antibodies, and 
respective fluorescent immunoassays were developed. 475 
 Concerning the antibody−coated competitive format, just an application has been reported 
for hapten analysis, specifically to clenbuterol detection in pig urine. Anti−clenbuterol antibodies 
were immobilized on magnetic Fe3O4/Au nanoparticles and later incubated with the analyte and a 
CdSe/CdS−clenbuterol conjugate. Finally, the particles were collected by magnetic forces and the 
fluorescence was recorded. This setup allows to concentrate the nanoparticles and to reach a very 480 
low limit of detection (LOD) and a wide lineal working range from 0.0005 to 20 ng/mL (Wang et al., 
2009d). 
LODs achieved using QD−based fluorescent assays are in the same range of enzymatic 
assays. Only few studies compare the sensitivity using different detection approaches for the same 
immunoassay against small−sized analytes, using exactly the same antibody and conjugates.  485 
Some studies reported a decrease in sensitivity of QD−based FLISAs as compared to their 
enzymatic counterparts. This fact has been ascribed to a loss in antigen binding capacity of the 
antibody when it is conjugated with the QD, but it also depends of the quality (affinity and 
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specificity) of the employed antibody (Jamieson et al., 2007), and the signal enhancement provided 
by an enzymatic label cannot be ruled out. Sensitivity was quantified for different drug assays with 490 
comparative ELISAs using QD−labelled and unlabelled antibodies. In one of those studies, the 
activity of the labelled antibody was determined to be 45–65% of that of the unlabelled antibody 
(Peng et al., 2009). However, Chen et al. (2010a, 2010b) compared QD−based FLISA with ELISA 
against the pesticide chlorpyrifos and they found improvements in sensitivity of 47−70%. Anyhow, 
thanks to the high affinity of antibodies, the obtained LODs are low enough to verify compliance of 495 
products with the legislation tolerances.  
 
6.2. Fluorescence (or Förster) resonance energy transfer  
FRET is a powerful technique that involves the nonradiative transfer of resonant 
fluorescence energy from an excited donor fluorophore to a ground−state acceptor fluorophore. 500 
The efficiency of the transfer depends on the degree of spectral overlap between donor emission 
and acceptor absorption, and on the distance between both fluorophores (Förster radius). Organic 
dyes and dark quenchers can be used as donors and acceptors, respectively, but they show some 
limitations, such as the fixed absorption/emission spectra, low chemical stability, pH dependence 
or photobleaching. However, QD nanoparticles can be employed as resonant energy donors due 505 
to: i) their size−tunable and narrow fluorescence spectra that allows a better control of the spectral 
overlap; ii) their wide absorption bands that permit an excitation wavelength far enough from the 
fluorescence signal; iii) the ability to be conjugated with different molecules and proteins; and, iv) 
their photostability and high quantum yield (Medintz et al., 2003). 
FRET is most efficient when the distance between donors and acceptors is in the 20–60 Å 510 
range, and it decreases with the sixth power of the separation distance between both fluorophores 
(Clapp et al., 2006a). Therefore, experimental designs must consider the anchoring of donor and 
acceptor particle as close as possible to maximize FRET phenomena. In this sense, QDs 
functionalized with small ligands (such as DHLA) and using small−sized biomolecules (like 
recombinant or fragmented antibodies) are preferred. On the contrary, the use of micelles or 515 
amphiphilic polymer functionalized QDs and/or conjugation with bridge proteins is discouraged. 
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Several studies can be found that develop FRET−based assays for the detection of low 
molecular weight analytes (see Table 6), using predominantly a QD as donor and an organic dye 
as acceptor. The simplest approach consists of assays where the direct interaction between the 
analyte and the QD surface promotes/inhibits the FRET phenomena. In this respect, a TNT FRET 520 
assay has been recently developed involving the electrostatic interaction between 
amino−terminated gold nanorods and carboxyl−terminated QDs (Xia et al., 2011). 
Organophosphorothioate pesticides have been analysed by using a dithizone−labelled CdTe 
conjugate that was initially quenched by FRET (dithizone acts as acceptor), and when the analyte 
was added dithizone ligands were replaced by the hydrolyzate of the respective 525 
organophosphorothioate pesticide and as consequence the QD fluorescence was restored (Zhang 
et al., 2010b). Also, a single−drop optical FRET sensor for the detection of polycyclic aromatic 
hydrocarbons (PAHs) has been developed using electrodeposited QDs on TiO2 nanotubes (Yang 
et al., 2010). All these strategies provide low specific assays and strong interferences are usually 
observed with related compounds. Thus, the incorporation of biomolecules (protein, antibody, or 530 
aptamer) to FRET designs improves considerably the selectivity of the assay. 
The first proposal of a QD−based FRET bioassay for haptens employed MBP, a protein 
with affinity to some sugars, including cyclodextrin and maltose. It consisted of a QD−MBP as 
FRET donor and a β−cyclodextrin−dye conjugate as acceptor. When the analyte (maltose in this 
case) was added, β−cyclodextrin−dye conjugate was displaced from MBP, and FRET 535 
phenomenon is inhibited; as a consequence, concentration−dependent fluorescence was 
generated (Medintz et al., 2003).  
The first reported immunoassay for a hapten employing QDs was reported by Goldman et 
al. (2005b). In that work, a TNT sensor was developed using antibody fragments conjugated to 
CdSe/ZnS QDs by means of polyhistidine tags. Then, a dye−labelled TNT analogue quenched the 540 
QD fluorescence by induced FRET, which was proportionally recovered with the addition of TNT 
(see Figure 8). Antibodies can be conjugated to QDs but also with the organic dye molecule, like in 
the development of a FRET−based assay to analyse biotin, fluorescein, and cortisol (Nikiforov and 
Beechem, 2006). In that case, antigen−labelled QDs and specific antibody (or streptavidin)−Alexa 
Fluor conjugates were employed as donor and acceptor, respectively. In the same way, a 545 
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competitive bioassay was developed to analyse 2,4−dichlorophenoxyacetic acid in water by means 
of the FRET phenomena produced between the antigen−labelled QD and the Cy5.5 dye−labelled 
antibody (Long et al. 2012). 
Aptamer–QD conjugates can be also employed for the development of FRET sensors for 
haptens, like for cocaine, where an anti−cocaine 3’−amine−terminated nucleic acid aptamer 550 
sequence was conjugated to CdSe/ZnS QDs, and a second 5’−amine−terminated aptamer 
sequence was conjugated to an organic dye. The complementarities of both oligonucleotides are 
insufficient to form a stable complex, but in the presence of the analyte a stable cocaine–aptamer 
supramolecular structure is stabilized and both fluorophores get closer, inducing FRET between 
QD and dye (see Figure 8) (Freeman et al., 2009a). 555 
Although QDs were initially proposed as FRET donors, some examples of QDs as 
acceptors can be found. QDs were considered inadequate acceptors when combined with 
molecular dyes as donors, because of lifetime incompatibility between QDs (>10 ns) and organic 
dyes (<10 ns), and light excitation continuously maintains QDs in the excited state (Algar et al., 
2010). However, lanthanides (with lifetimes in the ms range) can be used as donors because 560 
time−gating avoid a direct excitation of QDs. This approach was employed for the development of 
an estradiol assay, where a lanthanide isothiocyanate coupled to an analyte analogue was 
employed as donor and a QD−antibody conjugate as acceptor, being the QD fluorescence 
restored with the addition of estradiol (Harma et al., 2007). 
More recently, an innovative TNT sensor has been develop that uses two different size QDs 565 
as donor/acceptor system, and FRET is induced in this case by aggregation of both QDs driven by 
the interactions between TNT molecules and the amino groups of QD ligands (Shiraki et al., 2010). 
However, the aforementioned procedure shows a low selectivity because of the quenching effect 
can be also produced by other TNT analogues, such as 2,4−dinitrotoluene or nitrobenzene. 
All the aforementioned examples of FRET−based assays have very different designs, but 570 
their main common advantage is that they allow the development of homogeneous competitive 
bioassays, where the signal is directly measured after just an incubation step, without the need of 
cumbersome washing procedures. Nevertheless, the pH, the ionic strength, and sample 
21  
 
constituents may significantly affect the FRET phenomenon, so assay conditions must be carefully 
controlled (Jamieson et al., 2007). 575 
Analogous resonant energy transfer processes have also been developed, like 
bioluminescence resonance energy transfer (BRET) (So et al., 2006) and chemiluminescence 
resonance energy transfer (CRET) (Huang et al., 2006), where the excitation source is replaced by 
a luminescence light produced by a biological or chemical reaction, respectively, and QDs are 
employed as energy acceptors. In spite of the promising possibilities offered by these novel 580 
resonant energy transfer methodologies, they have been focused so far to in vivo imaging studies 
rather than to the development of diagnostic immunosensing devices (Frasco and Chaniotakis, 
2010). 
 
6.3. Immunosensors and related bioanalytical systems  585 
Most of the described bioassays for the detection and quantification of small analytes are 
based on FLISA and FRET technology. However, there are other immunoanalytical platforms that 
have been proposed for the detection of a variety of analytes using QDs. Table 7 shows the 
QD−based immunoassays found in literature for low molecular weight analytes excluding FLISA 
and FRET assays. As it can be seen, very different assays have been reported with techniques 590 
based on immunosensors, lateral flow immunoassays or the use of immunoreaction columns. 
Immunosensors can be defined as self−contained devices capable of providing specific 
analytical information using as biological recognition element an antibody or antibody fragment 
which is intimately associated with or integrated within a physicochemical transducer or 
transducing microsystem. Whether the degree of association or integration of the receptor with the 595 
transducer is sufficient or not as to rigorously include a particular analytical setup within the 
immunosensor concept is sometimes controversial, so the frontier between immunosensors and 
other immunoanalytical systems is frequently vague and uncertain. 
The implementation of QDs in immunosensors obviously relies on the composition, optical 
properties and electrochemical/electrochemiluminescent characteristics of these inorganic 600 
nanoparticles. The number of published papers concerning the application of QDs for the 
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development of immunosensors hardly exceeds one hundred, and just a handful deals with 
haptens as analytical targets. 
Electrochemiluminescence (ECL) is a powerful technique in analytical chemistry. In ECL, 
light is produced from electrochemically generated intermediates that undergo a highly exergonic 605 
reaction to generate an electronically excited state. ECL has several attractive features, including 
absence of a background optical signal, low cost, precise control of reaction kinetics, and 
opportunities to enhance intensity with nanomaterials such as metallic nanoparticles and 
nanotubes. Together, these features make ECL a highly sensitive and selective analytical method 
(Forster et al., 2009). After ECL of QDs in nonaqueous (Myung et al., 2002) and aqueous 610 
(Poznyak et al., 2004; Zou and Ju, 2004) solutions was first reported, a number of immunosensors 
based on this sensing principle has been published. For example, Zhu’s and Zhang’s research 
groups have described QD−based immunosensors for several model proteins and 
clinically−relevant markers (Jie et al. 2008a, 2008b, 2010, 2011; Li et al., 2011). In all these 
sensing schemes, different nanocomposites comprising QDs and target−specific antibodies were 615 
coated on gold electrodes, so upon addition of the analyte the formation of the immunocomplex 
inhibits the ECL reaction and therefore photoluminescence intensity gradually decreases with 
antigen concentration. Despite these remarkable precedents, to the best of our knowledge no 
paper has yet been published reporting the development of an ECL immunosensor with QDs for 
hapten detection, although application of the same sensing principles to small−sized analytes can 620 
easily be envisioned.  
Photoexcitation of semiconductor QDs not only leads to luminescence properties, but the 
photogenerated electron−hole species may also electrically communicate with electrode surfaces 
(Gill et al., 2008). Unlike ECL, in the photoelectrochemical detection process light is used to excite 
photoelectrochemically active species on the electrode and current is used as the detection signal. 625 
Some outstanding examples on the application of this sensing principle using semiconductor QDs 
and antibodies have been recently reported by Xu’s group (Wang et al., 2009a, 2009e; Zhao et al., 
2012a, 2012b). More pertinent to this review is the development of a label−free immunosensor for 
pentachlorophenol based on photoelectrochemical detection (Kang et al., 2010). In that work 
nanocrystals were deposited on the inner walls and surface of TiO2 nanotubes. Following 630 
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treatment with chitosan and glutaraldehyde, anti−pentachlorophenol antibodies were covalently 
conjugated on the nanotubes so the specific interaction of the analyte with the antibodies resulted 
in a decrease in the photocurrent. A linear response of the immunosensor in the 1–300 nM range, 
with an impressive limit of detection of 1 pM, was reported by the authors. Additional studies in this 
research line should contribute to extend this immunosensing principle to other relevant haptens. 635 
QDs as electrochemically active labels have also been employed in immunoanalytical 
devices. Most of the reported schemes have commonly relied on a highly sensitive electrochemical 
stripping measurement of the metal tag after dissolution of the QDs in acidic medium (Wang, 2007; 
de la Escosura−Muñiz, 2008, 2010; Guo and Dong, 2009). While most studies addressed the 
determination of single proteins using essentially a sandwich setup where an antibody is 640 
immobilized and the other is attached to QDs (Pinwattana et al., 2010; Chen et al., 2009c; Gu et 
al., 2011; Ho et al., 2009; Cui et al., 2007), examples of multiplexed applications with different 
antibodies coupled to semiconductor nanocrystales of different composition have also been 
reported (Liu et al., 2004; Zhou et al., 2010; Qian et al., 2011). Interestingly, Liu’s group has 
developed a strategy in which silica nanospheres with uniform size and excellent dispersion 645 
properties have been used as carriers for both QDs and antibodies, thus increasing sensitivity 
through signal amplification (Chen et al., 2009c). Furthermore, when different detection methods 
have been employed, electrochemistry resulted in lower detection limits than ECL and 
fluorescence (Qian et al., 2010; Yuan et al., 2011). Nevertheless, despite its enormous potential for 
the ultrasensitive detection of haptens, electrochemistry, like ECL, has not been yet applied to the 650 
immunodetection of small-sized analytes. 
QDs have also been successfully integrated in immunochromatographic test strips as 
electrochemical (Liu et al., 2009) and photoluminescence reporters (Li et al., 2010). The 
combination of semiconductor nanocrystals and lateral flow test strips hold the promise of resulting 
in portable, on−site point−of−care devices enabling the sensitive, rapid, and low−cost detection of 655 
trace amounts of relevant analytes, either proteins or haptens. Lin’s group has recently reported 
the development of QD−based immunochromatographic assays to trichloropyridinol, a biomarker 
of exposure to the worldwide employed organophosphorous insecticide chlorpyrifos (Zou et al., 
2010), and to cotinine, a nicotine metabolite (Nian et al., 2012). Both immunosensors are based on 
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a competitive immunoreaction tacking place on a nitrocellulose membrane, where the analyte 660 
competes with a QD−conjugated analogue for binding to the antibodies immobilized on the test 
zone. Remarkably, carboxy−functionalized derivatives of the analytes were directly covalently 
coupled to amino−modified QDs, instead of the most extended approach of attaching 
protein−hapten conjugates to the nanocrystals. The opposite strategy, i.e., immobilization of the 
protein−hapten conjugate on the test zone of the lateral flow immunostrip and antibody−coated 665 
QDs, has also been described for an assay to clenbuterol (Luo et al., 2011). Recently, silica 
nanoparticles coated with antibodies and QDs has been used as immunocomposites in an attempt 
to increase assay sensitivity (Bai et al., 2012). According to these authors, this amplification 
strategy provided a 10−fold more sensitive strip test than when conventional gold−based labels 
were used. Likewise, an innovative immunochromatographic test to ochratoxin A has been 670 
reported by Xu’s research group using QDs coupled to aptamers as receptors (Wang et al., 2011).   
The development of flow injection immunoassays for haptens employing QDs as labels has 
also been described. Chouhan et al. (2010) developed such a system to methyl−parathion, an 
organophosphorous insecticide. Specific anti−methyl−parathion antibodies were covalently 
immobilized on Sepharose, and the analyte and a fixed amount of a complex consisting of QDs 675 
coated with protein−hapten conjugates were sequentially passed through the column. The amount 
of complex not retained by the column was collected and its fluorescence determined, so a positive 
linear correlation between the analyte concentration and the recorded signal was obtained. Authors 
claimed an LOD for their immunoanalytical system that favourably compares with that of a classical 
competitive ELISA. The same research team has recently reported a similar system for 680 
2,4−dichlorophenoxyacetic acid, a widely applied herbicide,(Vinayaka et al., 2009). Finally, a 
column gel−based immunoassay for benzo[a]pyrene has been reported by Beloglazova et al. 
(2011). Remarkably, BSA−hapten conjugates were coupled to three different detection labels: the 
enzyme HRP, colloidal gold, and QDs. After successive incubation steps on Sepharose columns 
with immobilized antibody, cut−off levels of 5 pg/mL were obtained when HRP or QDs were used 685 
as reporters, whereas with colloidal gold the lowest concentration clearly distinguishable from the 
zero−dose concentration was estimated as 25 pg/mL. 
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Finally, Chen et al. (2009) described the development of a chip−based immunoassay for 
the rapid and sensitive determination of 7−aminoclonazepam, the major urinary metabolite of the 
benzodiazepine drug clonazepam. In that system, CdTe QDs were coated with denatured BSA to 690 
improve water solubility and then antibodies were covalently conjugated through EDC/NHS 
chemistry. OVA−hapten conjugates were used as competing reagents, so the detection principle 
was based on the mobility difference between the antibody and antibody–antigen complex. The 
whole procedure takes 5 min. The method was finally applied to the determination of 
7−aminoclonazepam residues in human urine, and the obtained results adequately correlated with 695 
those provided by ELISA and LC/MS/MS.   
 
6.4. Multiplex immunoassays 
One of the main advantages offered by immunoassays is the high specificity of the 
antigen−antibody interaction. However, some applications require the simultaneous analysis of 700 
several analytes on the same sample. This task cannot be performed neither using enzymatic 
immunoassays nor using organic dye−based fluorescent assays because of the overlapping of 
their broad emission spectra. Thus, the use of QDs as fluorescent labels may overcome these 
problems, considering their unique optical properties. Consequently, multiplex immunoassays can 
be easily developed, at least theoretically, by the conjugation of QDs of different size, and 705 
therefore with diverse fluorescence spectra, to specific antibodies against distinct analytes. The 
applicability of this detection principle was first demonstrated for the analysis of several toxins  by 
using multiplexed FLISAs with QDs (Goldman et al., 2004). Similar methodologies were later 
developed for the analysis of hapten molecules, such as the determination of five drugs 
(dexamethason, gentamicin, clonazepam, ceftiofur, and medroxyprogesterone) in pork muscle by 710 
means of independent and simultaneous FLISAs using  specific anti−drug antibodies conjugated 
by the avidin−bridge strategy to different QDs (Peng et al., 2009). Likewise, Hammock’s group 
explored the possibility of using QDs in multiplexed immunoassays by means of a microarray for 
the detection of 3−phenoxybenzoic acid and atrazine−mercapturate, two biomarkers of exposure to 
the pyrethroid insecticides and to the herbicide atrazine, respectively (Nichkova et al., 2007). 715 
Similarly, two generic antibodies for sulphonamides and quinolones were labelled with different 
26  
 
QDs to develop a multiplexed FLISA able to determine 20 different drugs in milk (Zhu et al., 2011). 
Interestingly, this multianalyte assay was used in combination with an enzymatic immunoassay for 
melamine analysis, thus wisely proving the compatibility of both detection methodologies. 
Multiplexing can also be applied to competitive FRET−based assays, such as in the 720 
simultaneous determination of biotin, fluorescein, and cortisol using antigen−labelled QDs and 
dye−labelled antibodies and streptavidin (Nikiforov and Beechem, 2006). 
Fiber optic evanescent wave biosensing platforms hold great promise for the development 
of QD−based immunosensors, particularly for multianalyte determination. A noteworthy 
proof−of−concept was reported by Zhang et al. (2010), who immobilized four different antibodies 725 
onto the surface of a single optical fibre and, using QD−labelled antigens, samples were 
interrogated for the presence of fibrinogen, serum albumins (human and bovine), and human IgG. 
Undoubtedly, the development of multiplexed immunoassays provides an invaluable tool for 
the monitoring of numerous analytes in environmental and food control programs, as well as in the 
clinical field, because they combine the multianalyte character of chromatographic reference 730 
procedures with the simplicity, low cost and sample throughput of antibody−based methods. 
Nevertheless, multiplex determination of more than 3 or 4 different analytes requires the use of 
deconvolution software to assign the whole fluorescence response to individual analytes. 
 
7. Conclusions and future trends 735 
The use of QDs as fluorescent markers of different biomolecules has started a wide number 
of biological applications such as bioassays, gene technology, cell tracking or in vivo imaging 
(Jamieson et al., 2007). The great acceptance of this promising technology is due to the 
combination of both, the excellent optical properties of QDs and the high specificity of the targeting 
biomolecules. 740 
We have focused this review study in the use of QDs in the development of different 
immunodetection schemes capable of specifically detecting small molecule chemicals, trying to 
explain the main features of this novel technology and the whole process steps, from the QD 
synthesis and surface functionalization, to the bioconjugation and assay development. The 
increasing number of related published papers has shown several new applications and novel 745 
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designs, mainly based on the development of innovative biosensors, FLISA procedures, 
multianalyte determinations, and homogeneous FRET sensors, because of the valuable 
advantages of QD compared to conventional fluorescent dyes. 
The main advantages that QDs offer in immunosensing are: i) higher sensitivity and stability 
than organic fluorophores; ii) size tuneable emission combined with broad absorption spectra allow 750 
multiplex immunoassays; and iii) the tuneable emission spectra simplifies the design of FRET 
assays. On the other hand, the main drawbacks of QD nanoparticles are: i) limited functionalization 
of ligands; ii) variable efficiency in the bioconjugation to antibodies; and iii) multiplexed assays 
require a data treatment to deconvolute signals.  
In our opinion the future trends and novel research related to the development of 755 
QD−based bioassays for the detection of chemicals will be oriented towards the improvement of 
next aspects: i) QD synthesis using smooth conditions and low toxicity reagents; ii) new coating 
strategies to obtain long−term stable, water−compatible, and functional QDs; iii) bioconjugation 
procedures with high efficiency, small size particle, and easy purification steps; iv) implementation 
of biomolecules with high specificity as recombinant antibodies or aptamers in the development of 760 
bioassays; and v) advances in robustness of QD−based immunosensors and extension of the 
developed methodologies to the detection of small−sized analytes. 
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Figure Legends 
Fig. 1 Dependence of fluorescence emission wavelengths of quantum dots on their chemical 
composition. 
 950 
Fig. 2 Accumulated number of published papers related to quantum dots until 2012 (ISI Web of 
Knowledge, Thomson Reuters). Inset: Distribution of published papers by main knowledge areas. 
 
Fig. 3 CdSe quantum dots obtained by Peng synthesis and different heating times: 3, 5, 7, 10, 
14, 20, 25 and 30 minutes. 955 
 
Fig. 4 Typical particle size of an antibody (A), a QD functionalized by ligand exchange with 
dihydrolipoic acid (B) and a QD coated with amphiphilic polymer (C). 
 
Fig. 5 Schematic representation of a typical IgG antibody and the fragments originating after 960 
reduction of disulphide bridges. Red circles show the active antigen recognition areas. 
 
Fig. 6 Most employed strategies for the bioconjugation of QDs with antibodies. Grey boxes 
indicate some undesired products that can be also generated. 
 965 
Fig. 7 Schematic diagram of competitive fluorescence−linked immunosorbent assay (FLISA).  
 
Fig. 8 Example of fluorescence resonance energy transfer (FRET) sensors using a 
QD−antibody conjugate (A) and a QD−aptamer structure (B). 
Table 1  
Examples of the most common synthesis procedures for the preparation of QDs 
 
Synthesis type QDs (core/shell) Precursors Grown temperature (ºC) Atmosphere Shell References 
Colloidal CdS, CdSe, CdTe Cd(CH3)2 in TOP 
Se, Te, (TMS)2S, (TMS)2Se or (BDMS)2Te in TOP 
190−320 Ar − Murray et al., 1993 
 CdSe/ZnSe Cd(CH3)2 in TOP/TOPO 
Se in TOP 
23−260 Ar Zn(C2H5)2, Se in TOP Danek et al., 1996 
 CdSe/ZnS Cd(CH3)2 in TOP/TOPO 
Se in TOP 
300−350 Ar Zn(CH3)2, (TMS)2S in TOP Hines and Guyot−Sionnest, 
1996 
 CdSe CdO, Se, HPA in TBP/TOPO 250 Ar − Peng and Peng, 2001 
 CdSe/ZnS Cd(acetylacetonate)2, Se, HDA, HDDO in TOP/TOPO 340−350 Ar/N2 Zn(Et)2, (TMS)2S in TOP Clapp et al., 2006b 
 CdSe/CdZnS Cd(myristate)2, Se, oleic acid in 1−octadecene 240 Ar Zn(oleate)2, Cd(oleate)2 in TOA Carion et al., 2007 
Aqueous CdS Cd(NO3)2, Na2S, Na(polyphosphate) 
Cd(NO3)2, Na2S, cysteine 
Cd(acetate)2, Na2S, 1−thioglycerol 
100 N2  − Chen and Rosenzweig, 
2002 
 CdS Cd(ClO4)2, H2S, thiourea, 1−thioglycerol 100 − − Vossmeyer et al., 1994 
 CdS CdCl2, Na2S, poly(N−vinyl−2−pyrrolidone) − − − Li et al., 2006 
 CdSe CdCl2, NaHSe, cysteine 90 N2 − Liu et al., 2009 
 ZnS ZnSO4, Na2S, cysteine 47 N2 − Kho et al., 2000 
 CdTe CdCl2, NaHTe, TGA 100 N2 − Bao et al., 2004 
 CdTe CdCl2, NaHTe, MPA  100 N2 − Chen et al., 2010a 
 Mn−doped ZnSe Zn(NO3)2, NaHSe, MnCl2, MPA 100 N2 − Wang et al., 2009b 
Note: BDMS, tert−butyldimethylsilyl; HDA, hexadecylamine; HDDO, 1,2−hexadecanediol; HPA, hexylphosphonic acid; MPA, 3−mercaptopropionic acid; TBP, tributylphosphine; TGA, thyoglycolic acid; TMS, trimethylsilyl; TOA, 
trioctylamine;TOP, trioctylphosphine; TOPO, trioctylphosphine oxide. 
  
Table(s)
Table 2 
Strategies for water solubilisation of CdSe/ZnS QDs capped with TOP/TOPO. 
 
Coating Examples  References 
Ligand exchange 
 
   
Monodentate thiols Mercaptoacetic acid, mercaptopropionic acid 
HS
OH
O      OH
O
HS  
Chan and Nie, 1998; 
Vinayaka et al., 2009; Wang 
et al., 2009b 
 
 Mercaptoethane sulfonate 
HS
S
O-
OO
 
Jin et al.,2005 
 1−thioglycerol HS
OH
OH
 
Vossmeyer et al., 1994 
 tert−butyl−N−(2−mercaptoethyl)−carbamate 
HS
H
N O
O  
Jin et al.,  2004 
 2−(mercaptoethyl)trimethylammonium chloride 
HS
N+ Cl-
 
Callan et al., 2008 
 2−(dimethylamino)ethanethiol 
HS
N
 
Li et al., 2008b 
Didentate thiols Dihydrolipoic acid 
SH
OH
O
SH  
Clapp et al., 2006b 
 N−methyl−n−[2−(methylamino)ethyl]−dihidrolipoamide 
SH
N
O
SH
H
N
 
Yan et al., 2010 
PEG−derivatives Hidroxy−PEG−dihydrolipoate 
SH
O
O
SH
O
OH
n
 
Uyeda et al., 2005 
 Amine− terminated PEG−dihydrolipoamide 
SH
N
H
O
SH
O
NH2n
 
Liu et al., 2008 
 Carboxylic acid−terminated PEG−dihydrolipoamide 
SH
N
H
O
SH
O
N
Hn
OH
O O
 
Liu et al., 2008 
Silanization 3−mercaptopropyltrimetoxysilane 
HS Si OH
OH
OH  
Bruchez et al., 1998 
Other Cysteine 
HS OH
NH2
O
 
Zhang et al., 2008b 
 
 Tris(2−aminoethyl)amine + carbon disulfide 
HS N
H
S
N
NH2
NH2
 
Wang et al., 2009c 
 Dithizone 
H
N
N
H
N
N
S
 
Zhang et al.,  2010b 
 Functionalized phosphines 
*
H
N O P O
O O
H
N *
OR
n  
R =           
N
H
O
, 
N
H
OH
O O
 , 
N
H
O
O
O  
Kim and Bawendi, 2003 
 Denatured bovine serum albumin BSA−SH Peng et al., 2009 
Hydrophobic interaction 
 
   
Amphiphilic polymer Poly(maleic anhydride alt−1−tetradecene) 
Poly(maleic anhydride−alt−1−octadecene) 
Poly(maleic anhydride−alt−1−dodecene) 
O OO
*
* (CH2)nCH3
n  
Lin et al., 2008; Pellegrino et 
al., 2004; Yan et al., 2010 
Phospholipid micelles Phosphatidylcholine 
PO O
O
O-
N+
O
O
CH3(CH2)14
O
O
CH3(CH2)14
 
Dubertret et al., 2002 
 1,2−dipalmitoyl−sn−glycero−3−phosphoethanolamine−N−methoxy−PEG 
PO O
O
OH
H
N
O
O
CH3(CH2)14
O
O
CH3(CH2)14
O
O
n
 
Carion et al., 2007 
Note: PEG, poly(ethylene glycol); BSA, bovine serum albumin. 
 
  
Table 3 
Commercially available quantum dots and most relevant information 
 
Company QD (core/shell) Emission 
range (nm) 
Funcionalized QDs Bioconjugated with Web page 
Attonuclei (Nantes, France) ZnS − − − www.attonuclei.com 
CAN GmbH (Hamburg, Germany) CdSe, CdSe/CdS, CdSe/CdS/ZnS 480−620 − − www.can−hamburg.de 
Crystalplex (Pittsburgh, PA, USA) CdSeS/ZnS 450−685 Carboxyl, amino, hydroxyl − www.crystalplex.com 
Evident Technologies (Troy, NY, USA) InGaP/ZnS 650−680 Carboxyl, amino, biotin − www.evidenttech.com 
Life Technologies (Carlsbad, CA, USA)  
 
CdSe/ZnS, CdTe/ZnS 525−800 Carboxyl, amino, biotin Streptavidin, isotype antibody, 
anti−fluorescein, 
anti−dinitrophenol, GAC, GAH, 
GAM, GAR, GARt, HAM, MAH, 
RAG, RtAM 
www.lifetechnologies.com 
MKnano (Toronto, Canada) CdS, CdSe, CdSe/ZnS, CdTe, PbS, 
InP/ZnS 
360−1500 Carboxyl − www.mknano.com 
Nanoco Group PLC (Manchester, England) CdS, CdSe, CdSe/ZnS, Cd−free 460−640 Carboxyl, amino − www.nanocotechnologies.com 
www.sigmaaldrich.com 
Nanomaterials & nanofabrication laboratories (Fayetteville, AR, USA)  CdS, CdSe, CdSe/ZnS 360−640 − − www.nn−labs.com 
Ocean Nanotech (Springdale, AR, USA) CdSe, CdSe/ZnS 500−630 Carboxyl, amino − www.oceannanotech.com 
PlasmaChem GmbH (Berlin, Germany) CdTe, CdSe/ZnS, ZnCdSe/ZnS 510−780 Carboxyl  www.plasmachem.com 
Reinste Nano Ventures Pvt. Ltd (Noida, India) CdTe, CdSe/ZnSe, ZnCdSe/ZnS 440−780 Carboxyl, amino − www.reinste.com 
Wuhan Jiayuan QuantumDots Co., Ltd (Wuhan, China) CdSe/ZnS 525−625 Carboxyl, amino Streptavidin, GAM, GAR www.qds.net.cn 
Note: GAC, goat anti−chicken; GAH, goat anti−human; GAM, goat anti−mouse; GAR, goat anti−rabbit; GARt, goat anti−rat; HAM, hamster anti−mouse; MAH, mouse anti−human; PEG, polyethylene glycol; RAG, rabbit anti−goat; RtAM, 
rat anti−mouse.  
Table 4 
Comparison of the most employed QD−antibody conjugation procedures. 
 
Method Advantages Drawbacks 
Active ester  Simple 
 Easy 
 Common reagents 
 Small size 
 Also valid for other proteins 
 
 Aggregate formation 
 Crosslinking 
 Buffer incompatibility  
Activated maleimide  Orientated  antibody 
 Small size 
 
 Critical antibody reduction 
 Poor functionality 
 Buffer incompatibility 
 
Avidin bridge  Stable interaction 
 Streptavidin−QDs are commercially available 
 Also valid for other proteins 
 
 Big size 
 Requires protein biotinylation 
 On column reaction 
 Heterogeneous protein/QD ratio 
 
Protein G bridge  Orientated  antibody 
 Stable interaction 
 
 Big size 
 Requires engineering proteins 
 Heterogeneous protein/QD ratio 
 
Polyhistidine tags  Small size particles 
 Improves FRET efficiency 
 Stable interaction 
 Requires engineering proteins 
Note: Detailed procedures for each conjugation methods can be found in Clapp et al. (2006), Peng et al. (2009), Xing et al. (2007) and www.lifetechnologies.com. 
 
 
  
Table 5 
Quantum dot based fluorescence−linked immunosorbent assays (FLISAs) for haptens found in literature. 
 
Analyte Classification QD QD conjugated to QD conjugation 
method 
Sample Recovery (%) RSD (%) LOD (ppb) References 
Sulfamethazine Drug  Qdot  a Secondary antibody Commercial Chicken muscle 81−117 7−10 1.0 Ding et al., 2006 
Sulfamethazine, N4-acetyl sulfamethazine, 
sulfadimethoxine, sulfamerazine 
Drug Qdot a Specific antibody DTT/SMCC Milk 94−106 2−9 0.6 Shen et al., 2007 
β−methasone Drug ZnS/CdSe Secondary antibody − Chicken muscle − − 0.1 Yuan et al., 2008 
Clenbuterol Drug CdSe/CdS Antigen − Pig urine 87−117 − 0.0005 Wang et al., 
2009d 
Enrofloxacin Drug Qdot a Secondary antibody Commercial Chicken muscle 81−94 10−13 2.5 Chen et al., 
2009a 
Enrofloxacin, ciprofloxacin, norfloxacin, 
flumequine, difloxacin, sarafloxacin, 
pefloxacin methanesulfonate, ofloxacin, 
lomefloxacin, enoxacin, danofloxacin, oxolinic 
acid, marbofloxacin, sulfadiazine, 
sulfapyridine, sulfamethazine, sulfamethizole, 
sulfamerazine, sulfamonomethoxine, 
Drug Qdot a Secondary antibody, streptavidin Commercial Milk 84−107 6–14 0.2 Zhu et al., 2011 
Dexamethason, gentamicin, clonazepam, 
ceftiofur, medroxyprogesterone 
Drug  CdTe Biotinylated denatured BSA Avidin Pork muscle 61−87 9−14 0.06−0.16 Peng et al., 2009 
Chlorpyrifos Pesticide CdTe Secondary antibody  Drinking water 91−108 7−15 8.4 Chen et al., 
2010b 
Chlorpyrifos Pesticide CdTe Streptavidin EDC/sNHS Drinking water 86−105 6−13 3.8 Chen et al., 
2010a 
2,4,6−trinitrotoluene Explosive CdSe/ZnS Specific antibody Protein G − − − − Goldman et al., 
2002a 
2,4,6−trinitrobenzene 
hexahydro−1,3,5−trinitro−1,3,5−triazine 
Explosive CdSe/ZnS Specific antibody Protein G, avidin − − − 500 Goldman et al., 
2002c 
2,4,6−trinitrotoluene Explosive CdSe/ZnS Recombinant antibody Polyhistidine − − − 41 Goldman et al., 
2005a 
Aflatoxin B1 Toxin CdSe/ZnS Specific antibody EDC − − − − Fernández−Argüe
lles et al., 2008 
Deoxynivalenol Toxin CdTe/CdS Specific antibody EDC/NHS Wheat flour 99−103 3−5 0.038 Shuping et al., 
2011 
Microcystin−LR Toxin CdSe/CdS Specific antibody EDC Water 96−104 1 0.069 Zhou et al., 2011 
17 β−oestradiol Hormone Streptavidin−QD b Biotinylated secondary antibody Commercial Water 86−113 − 0.005 Sun et al., 2010 
Progesterone Hormone CdSe/ZnS BSA−antigen EDC Bovine milk 88−100 1−3 0.1 Trapiella−Alfonso 
et al., 2011a 
Fluoranthene PAH c CdTe Specific antibody EDC/NHS Water 95−111 9 0.013 Ye et al., 2010 
Perfluorooctane sulfonate Surfactant Streptavidin−QD b Biotinylated DNA probe Commercial Water 108 − 0.0025 Zhang et al., 2011 
a from Life Technologies (Carlsbad, CA, USA)  
b from Wuhan Jiayuan QuantumDots Co., Ltd (Wuhan, China) 
Note: BSA, bovine serum albumin; EDC, 1−Ethyl−3−(3−dimethylaminopropyl)carbodiimide; LOD, limit of detection; NHS, N−hydroxysuccinimide; sNHS, N−hydroxysulfosuccinimide; PAH, polycyclic aromatic hydrocarbon; QD, 
quantum dot; RSD relative standard deviation. 
  
 Table 6 
Quantum dot based fluorescence resonance energy transfer (FRET) studies for haptens found in literature. 
 
Analyte Classification Donor Acceptor Sample Recovery 
 (%) 
RSD (%) LOD (ppb) References 
Maltose Sugar CdSe/ZnS−MBP−zb  QSY9−labelled CD − − − − Medintz et al., 
2003 
2,4,6−trinitrotoluene Explosive CdSe/ZnS−antibody fragment 
 
Black hole quencher 10−labelled TNT Soil 40−80 30−48 20 Goldman et al., 
2005b 
2,4,6−trinitrotoluene Explosive Amino−Qdota Amino−Qdota − − − 0.001 Shiraki et al., 
2010 
2,4,6−trinitrotoluene Explosive MPA−coated CdTe/CdS Cisteamine−labelled Au nanorods Environmental − − 0.02 Xia et al., 2011 
2,4,6−trinitrotoluene Explosive CdS−antibody Ruthenium chelate−based aminoacid 
monomer 
− − − − Say et al., 2012 
Estradiol, biotin Hormone, vitamin Antigen−labelled Eu and Tb isothiocyanato chelate CdTe−labelled streptavidin and antibody 
fragment 
− − 2−11 0.3 Harma et al., 
2007 
Biotin, fluorescein, cortisol  Hormone, other Antigen−labelled Amino−Qdot a Alexa Fluor dye−labelled streptavidin and 
antibody 
− − − 0.7 Nikiforov and 
Beechem et al., 
2006 
Chlorpyrifos Pesticide CdTe Dithizone Apple 92−132  5.5 Zhang et al., 
2010b 
2,4-dichlorophenoxyacetic 
acid 
Pesticide Antigen−BSA−labelled Amino−Qdota Cy5.5−labelled antibody Water 91-103 1-6 0.1 Long et al., 2012 
Benzo(a)pyrene PAH CdTe Benzo(a)pyrene Drinking water 92−118 1−10 0.004 Yang et al., 2010 
Cocaine Drug CdSe/ZnS−aptamer Atto 590 dye−labelled aptamer − − − 300 Freeman et al., 
2009a 
a QDs from Life Technologies (Carlsbad, CA, USA)  
Note: BSA, bovine serum albumin; CD, β−cyclodextrin; HRP, horseradish peroxidase; GOD, glucose oxidase; LOD, limit of detection; MBP−zb, maltose binding protein with a leucine zipper; MPA, 3−mercaptopropionic acid; PAH, 
polycyclic aromatic hydrocarbon; QD, quantum dot; RSD relative standard deviation. 
  
Table 7 
Quantum dot based immunosensors and related immunoanalytical systems for haptens found in literature. 
 
Immunoassay type Compound Detection QD Sample Recovery (%) RSD (%) LOD (ppb) Reference 
Photoelectrochemical  Pentachlorophenol Photocurrent intensity CdSeTe River water 99−102 6−7 0.0003 Kang et al., 2010 
Immunochromatographic 3,5,6−trichloropyridinol Electrochemical Qdot a Rat plasma 77−130 − 1 Zou et al., 2010 
 Cotinine Fluorescence Qdot a Human serum 95-110 6 1 Nian et al. 2012 
 Clenbuterol Fluorescence QSH b − − − 30 Luo et al., 2011 
 Ochratoxin A Fluorescence - Water − 5 2 Wang et al. 2011 
Flow injection Methyl−parathion Fluorescence CdTe Water 84–103 0.2–7.0 0.1 Chouhan et al., 2010 
 2,4−dichlorophenoxyacetic acid Fluorescence CdTe − − − 0.3 Vinayaka et al., 2009 
Column gel Benzo[a]pyrene Fluorescence CdTe − − − 0.005 Beloglazova et al., 2011 
Chip 7−aminoclonazepam Fluorescence CdTe Human urine 90−101 5 0.02 Chen et al., 2009b 
a QDs from Life Technologies (Carlsbad, CA, USA)  
b QDs from Ocean Nanotech (Springdale, AR, USA) 
Note: LOD, limit of detection; QD, quantum dot; RSD, relative standard deviation. 
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